Tissue microarray-based analysis shows phospho-β-catenin expression in malignant melanoma is associated with poor outcome

International Journal of Cancer

Volumn 103, Issue 5, 2003, Pages 652-656

  Kielhorn, Eric ^a   Provost, Elayne ^a   Olsen, Drew ^a   D'Aquila, Thomas G ^a   Smith, Bradley L ^b   Camp, Robert L ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CELL SIGNALING TECHNOLOGY   (United States)

Author keywords

APC; Cadherin; Cell adhesion; Outcome; Signal transduction; Wnt pathway

Indexed keywords

BETA CATENIN; CELL PROTEIN; PHOSPHO BETA CATENIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; CELL ADHESION; CONTROLLED STUDY; DNA MICROARRAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BETA CATENIN; CELL NUCLEUS; CYTOSKELETAL PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE; TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037455843     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10893     Document Type: Article

References (28)

1. Polakis P. More than one way to skin a catenin. Cell 2001;105:563-6.
2. Barker N, Clevers H. Catenins, Wnt signaling and cancer. Bioessays 2000;22:961-5.
3. Morin PJ. Beta-catenin signaling and cancer. Bioessays 1999;21: 1021-30.
4. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, Dacosta LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of C-Myc as a target of the Apc pathway. Science 1998;281:1509-12.
5. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJH, Rubinfeld B, Polakis P, Matrisian LM. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999;18:2883-91.
6. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999;155:1033-8.
7. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
8. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999;96:5522-7.
9. Wijnhoven BPL, Dinjens WNM, Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000;87: 992-1005.
10. Chan EF. Gat U, McNiff JM, Fuchs E. A common human skin tumour is caused by activating mutations in beta-catenin. Nat Genet 1999;21: 410-3.
11. Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol 2001;158: 1005-10.
12. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999;59:1811-5.
13. Moreno-Bueno G, Gamallo C, Perez-Gallego L, de Mora JC, Suarez A, Palacios J. Beta-catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 2001;10:116-22.
14. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999;154:325-9.
15. Omholt K, Platz A, Ringborg U, Hansson J. Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNBI exon 3 mutations in cutaneous malignant melanoma. Int J Cancer 2001;92: 839-42.
16. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Houghton A Jr, Kirkwood JM, Mihm MF, Morton DL, Reintgen D, Ross MI, Sober A. Soong SJ, Thompson JA, Thompson JF, Gershenwald JE, McMasters KM. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000;88: 1484-91.
17. Duncan LM, Deeds J, Cronin FE, Donovan M, Sober AJ, Kauffman M, McCarthy JJ. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 2001;19:568-76.
18. Rimm D, Camp R, Charette L, Costa J, Olsen D, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001;7:24-31.
19. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-9.
20. Perrone EE, Theoharis C, Mucci NR, Hayasaka S, Taylor JM, Cooney KA, Rubin MA. Tissue microarray assessment of prostate cancer tumor proliferation in African-American and White men. J Natl Cancer Inst 2000;92:937-9.
21. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Brennan MF, Lewis JJ, Cordon-Cardo C. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001;158:1245-51.
22. Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, Rimm DL. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clin Cancer Res 2001;7:4013-20.
23. Pukkila MJ, Virtaniemi JA, Kumpulainen EJ, Pirinen RT, Johansson RT, Valtonen HJ, Juhola MT, Kosma VM. Nuclear beta catenin expression is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma. J Clin Pathol 2001;54: 42-7.
24. Hugh TJ, Dillon SA, Taylor BA, Pignatelli M, Poston GJ, Kinsella AR. Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer 1999;80:1046-51.
25. Ougolkov A, Mai M, Takahashi Y, Omote K, Bilim V, Shimizu A, Minamoto T. Altered expression of beta-catenin and c-erbB-2 in early gastric cancer. J Exp Clin Cancer Res 2000;19:349-55.
26. Samowitz WS, Powers MD, Spirio LN, Nollet F, van Roy F, Slattery ML. β-Catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res 1999;59:1442-4.
27. Latres E, Chiaur DS, Pagano M. The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 1999;18:849-54.
28. Matsuzawa S, Reed JC, Siah-l, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 2001;7:915-26.